Literature DB >> 2317564

Immunoglobulin G subclass deficiency and pneumococcal infection after allogeneic bone marrow transplantation.

J F Sheridan1, P J Tutschka, D D Sedmak, E A Copelan.   

Abstract

Serum immunoglobulin (Ig) G subclass levels were measured in a radial immunodiffusion assay in 25 leukemic patients before and after allogenic bone marrow transplantation. All patients received a conditioning regimen of busulfan and cyclophosphamide followed by infusion of marrow from an HLA-identical sibling. Intravenous infusions of a commercial Ig preparation were administered every 2 weeks until day 120 posttransplant. Nine patients developed pneumococcal infections at 6 months or greater posttransplant. Infection was associated with low levels or the absence of detectable serum IgG2 and IgG4. At the time of infection, 4 of 7 patients evaluated had undetectable IgG2, while 5 of 7 had undetectable levels of IgG4. After infection, none of the 8 patients evaluated had detectable levels of IgG2, and only 2 of 8 had detectable levels of IgG4. In contrast, all 16 patients without pneumococcal infection had IgG2 levels of 102 mg/dL or greater, and IgG4 levels of 20 mg/dL or greater. It appears that IgG2 and IgG4 subclass deficiencies after allogenic bone marrow transplantation contribute to susceptibility to pneumococcal infection. After pneumococcal infection, IgG2 and IgG4 levels remain low for a prolonged period and patients remain susceptible to infection by encapsulated organisms.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2317564

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Memory B lymphocytes determine repertoire oligoclonality early after haematopoietic stem cell transplantation.

Authors:  B Omazic; I Lundkvist; J Mattsson; J Permert; I Nasman-Bjork
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

Review 2.  Immune reconstitution following bone marrow transplantation.

Authors:  U N Verma; A Mazumder
Journal:  Cancer Immunol Immunother       Date:  1993-11       Impact factor: 6.968

3.  Analysis of immunoglobulin isotype levels in acute pneumococcal bacteremia and in convalescence.

Authors:  K Ekdahl; J Rollof; V A Oxelius; J Engellau; J H Braconier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-05       Impact factor: 3.267

4.  Pneumococcal immunity and response to immunization with pneumococcal vaccine in bone marrow transplant patients: the influence of graft versus host reaction.

Authors:  V Hammarström; K Pauksen; J Azinge; G Oberg; P Ljungman
Journal:  Support Care Cancer       Date:  1993-07       Impact factor: 3.603

5.  Antibody response to pneumococcal vaccine in children receiving bone marrow transplantation.

Authors:  M A Avanzini; A M Carra; R Maccario; M Zecca; P Pignatti; M Marconi; P Comoli; F Bonetti; P De Stefano; F Locatelli
Journal:  J Clin Immunol       Date:  1995-05       Impact factor: 8.317

Review 6.  Pneumococcal polysaccharide vaccines: indications, efficacy and recommendations.

Authors:  G A Bruyn; R van Furth
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-11       Impact factor: 3.267

7.  Functional hyposplenism following allogeneic bone marrow transplantation.

Authors:  R J Cuthbert; A Iqbal; A Gates; P J Toghill; N H Russell
Journal:  J Clin Pathol       Date:  1995-03       Impact factor: 3.411

Review 8.  Associating Changes in the Immune System with Clinical Diseases for Interpretation in Risk Assessment.

Authors:  Jamie C DeWitt; Dori R Germolec; Robert W Luebke; Victor J Johnson
Journal:  Curr Protoc Toxicol       Date:  2016-02-01

9.  Associating changes in the immune system with clinical diseases for interpretation in risk assessment.

Authors:  Michael I Luster; Dori R Germolec; Christine G Parks; Laura Blaciforti; Michael Kashon; Robert Luebke
Journal:  Curr Protoc Toxicol       Date:  2004

Review 10.  Epidemiology of infections in cancer patients.

Authors:  Teresa R Zembower
Journal:  Cancer Treat Res       Date:  2014
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.